An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and ...

Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage ...

RXRX opened at $4.83 on Friday. The business’s 50 day moving average is $5.34 and its 200-day moving average is $5.32. The stock has a market cap of $2.10 billion, a PE ratio of -2.71 and a beta of ...